The U.S. Food and Drug Administration (FDA) has granted accelerated approval to bluebird bio's gene therapy, Skysona (elivaldogene autotemcel), for boys aged 4 to 17 with early, active cerebral adrenoleukodystrophy (CALD). This milestone, announced on September 19, 2022, is significant not only for the CALD community but also offers a beacon of hope and demonstrates progress for the broader rare disease community, including those affected by inherited retinal diseases (IRDs).
A Step Forward in Gene Therapy
Skysona is the first gene therapy approved for active CALD, a rare and fatal neurodegenerative disease that primarily affects young boys. CALD is caused by mutations in the ABCD1 gene, leading to the accumulation of very long-chain fatty acids that damage the protective myelin sheath around nerve cells in the brain and spinal cord. The one-time treatment works by adding functional copies of the ABCD1 gene to a patient's own stem cells, helping to produce the necessary protein.
This approval marks bluebird bio's second gene therapy approval within a month, following their approval for beta-thalassemia. The FDA's decision was based on data from clinical trials, including the phase 2/3 study ALD-102 (Starbeam) and phase 3 study ALD-104. These studies showed that patients treated with eli-cel had an estimated 72% likelihood of major functional disability-free survival at 24 months, compared to 43% in untreated patients. The therapy is approved for boys between the ages of 4 and 17, regardless of whether they have a matched stem cell donor, which is crucial as 70% of CALD patients lack such a donor.
What This Means for Patients and Families
The accelerated approval pathway used for Skysona is a regulatory mechanism designed to expedite the availability of treatments for serious or life-threatening conditions with unmet medical needs. This pathway allows for approval based on surrogate endpoints that are reasonably likely to predict clinical benefit, with confirmatory trials still required. For the IRD community, this demonstrates the FDA's commitment to facilitating access to innovative therapies for rare genetic conditions.
While Skysona addresses a brain disease, its approval underscores the potential of gene therapy as a transformative approach for a wide range of genetic disorders, including those causing blindness. The success in navigating the regulatory landscape for CALD provides valuable insights and momentum for ongoing research and development in inherited retinal diseases. The FDA has previously approved gene therapies for inherited conditions, such as Luxturna for certain IRDs in 2017.
Looking Ahead
The approval of Skysona reinforces the growing landscape of gene therapies for rare diseases. As research continues to advance, the IRD community can look to these developments as a positive indicator of future therapeutic options. The FDA's continued support for accelerated approval pathways for rare and serious conditions suggests a promising future for delivering life-changing treatments to patients who need them most.